Greg Gianforte sold Astellas Pharma Inc (PINK: ALPMY)
Greg Gianforte (R-MT), a U.S. Representative, has disclosed 1 trade in Astellas Pharma Inc (ALPMY) since 2018, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Greg Gianforte sold $1,001 - $15,000 of Astellas Pharma Inc (PINK: ALPMY) on November 19, 2018. Since that trade, ALPMY is up +32.72% against the S&P 500 up +204.01%, an outperformance of -171.29%.
Data updated
Greg Gianforte's ALPMY trades vs the price
ALPMY is up +32.72% since Greg Gianforte sold on November 19, 2018, versus +204.01% for the S&P 500.
Performance since this trade
All Greg Gianforte ALPMY trades
Greg Gianforte & ALPMY trading FAQ
Is it legal for Greg Gianforte to trade Astellas Pharma Inc (ALPMY) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Astellas Pharma Inc (ALPMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Greg Gianforte sell ALPMY?
Greg Gianforte disclosed a sale of $1,001 - $15,000 of Astellas Pharma Inc (ALPMY) on November 19, 2018, according to public STOCK Act filings.
How has ALPMY performed since Greg Gianforte's trade?
Since Greg Gianforte sold ALPMY on November 19, 2018, the stock is up +32.72%, versus +204.01% for the S&P 500 over the same period, an outperformance of -171.29%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional ALPMY trades?
Quantellect tracks every disclosed congressional trade in Astellas Pharma Inc (ALPMY) on the Astellas Pharma Inc congressional trading page, which aggregates filings across all members of Congress.
Greg Gianforte's ALPMY tradesAll congressional filings for Astellas Pharma IncGreg Gianforte's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.